Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT05573425 Completed - Acne Scar Clinical Trials

Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars

Start date: August 22, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study was to compare the Efficacy of Topical Tazarotene gel 0.1% versus Microneedling in atrophic Post acne scars. All patients of age 18-40 years, with grade 2 to grade 4 facial atrophic acne scars, assessed using the Goodman and Baron qualitative global scarring grading. Group A was given daily home application of Topical Tazarotene gel 0.1% while on Group B, Microneedling monthly sessions done for 12 weeks. The results were assessed by photographs, Goodman and Baron Qualitative Acne Scars Grading system at the start and end of treatment. SPSS 21 was used for data analysis which showed comparable efficacy of daily home based application of Topical Tazarotene gel 0.1% versus Microneedling monthly sessions in Atrophic Post Acne Scars.

NCT ID: NCT05550337 Completed - Acne Vulgaris Clinical Trials

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

Start date: September 19, 2022
Phase: Phase 3
Study type: Interventional

To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.

NCT ID: NCT05529888 Completed - Acne Vulgaris Clinical Trials

Measure the Serum Level of Homocysteine in Acne Patients Before and After Oral Isotretinoin.

Start date: December 15, 2020
Phase: Phase 4
Study type: Interventional

Serum homocysteine level in Acne patients before and after oral Isotretinoin and Correlation between serum level of homocysteine in acne patients before and after Oral isotretinoin treatment

NCT ID: NCT05486910 Completed - Acne Clinical Trials

Management of Side-Effects of Anti-Acne Treatment by a Cosmetic Routine

Start date: April 29, 2021
Phase:
Study type: Observational

Retinoid-based topical acne treatment may induce local tolerance issues such as erythema, dryness, stinging and burning sensations that may reduce adherence and efficacy. The tested regimen (cream and cleanser) has been specifically developed to rebalance the skin microbiome and compensate side-effects of topical treatments (hydration, skin barrier repair) together with an action on skin imperfections and marks. This open-label study was conducted in subjects aged 12 years and over with sensitive skin (>2 on a sensitivity composite score from 0-3) treated for at least one month with the fixed-dose gel combination and presenting with treatment-related skin intolerance.

NCT ID: NCT05478330 Completed - Clinical trials for Acne Vulgaris Superficial Mixed Comedonal and Inflammatory

Evaluation of Efficacy of Topical Flutamide in the Treatment of Acne Vulgaris

Start date: January 13, 2021
Phase: N/A
Study type: Interventional

From the obtained results, topical Flutamide 1% gel can be a promising, effective, and safe alternative in treating patients with acne vulgaris with minimal side effects.

NCT ID: NCT05457621 Completed - Acne Vulgaris Clinical Trials

Effectiveness and Tolerance of Effaclar Serum in Women With Mandibular Acne

Start date: January 21, 2021
Phase: N/A
Study type: Interventional

The role of "dermocosmetics" in acne management is increasingly important, as many patients and even physicians now resort to them as first-line management in mild-to-moderate acne. The aim of the study is to demonstrate the efficacy of the tested product on the appearance of acne lesions in 30 adult women suffering from acne in the mandible following an active anti-acne therapy (systemic or topical). This study includes 2 months of cosmetic treatment with EFFACLAR Ultra Concentrated Serum and one month of followup without any treatment but a moisturizer with a daily UV protection. The investigational product has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. This product is expected: - to leave the skin clean and smooth, - to help unblock pores, - to exfoliate dead skin cells and help the skin to appear smoother, softer and pore-less, - to be non-comedogenic.

NCT ID: NCT05446402 Completed - Acne Clinical Trials

Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne

Start date: June 15, 2022
Phase: Phase 4
Study type: Interventional

The objective of this study is to compare tolerability of two similar commercially available over the counter acne regimens (Geologie and Proactiv) in individuals with mild to moderate acne vulgaris over a 12-week daily treatment course.

NCT ID: NCT05428449 Completed - Acne Vulgaris Clinical Trials

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Start date: February 10, 2022
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia(AGA) or acne

NCT ID: NCT05413200 Completed - Acne Vulgaris Clinical Trials

Investigation of the Effect of Oral Isotretinoin on Skin Thickness and Elasticity in Patients With Atrophic Acne Scar

Start date: November 1, 2021
Phase:
Study type: Observational [Patient Registry]

Acne scar is a common complication of acne vulgaris (AV). Early and effective treatment of AV has a crucial role in managing both acne and acne scarring. Oral isotretinoin (OI) is a widely preferred agent in treating moderate and severe AV worldwide. It has been shown that topical retinoids can also be effective in the treatment of atrophic acne scars. However, there is no study in the literature evaluating the effectiveness of OI protocol on atrophic scars with objective data. With the developing sonoelastography technology in recent years, a quantitative, objective, and reliable examination of the elasticity of the skin and subcutaneous tissue can be provided. In this study, for a detailed and objective evaluation of the effects of OI on atrophic acne scars, we investigate the AV severity, atrophic scar grade, scar size (SS), dermis and subcutaneous tissue thickness (STT), and changes in scar and subcutaneous tissue elastic modulus (EM) in moderate and severe AV patients with atrophic acne scars by clinical observation and SWE. Materials and Methods: It was designed as a single-center, prospective and observational study. Ethics committee approval was obtained. Thirty patients who applied to the Istanbul Training and Research Hospital, Dermatology Department, between November 2021 and January 2022 diagnosed with moderate and severe AV accompanied by atrophic acne scars were included in the study. Demographic characteristics of the patients were recorded. We started the OI with a standard dose regime. On days 0 and 90 of treatment, each patient's AV and scar severity; were evaluated with the global acne grading system (GAGS) and the Goodman and Baron Qualitative Global Scar Rating System (GSRS). On the same days, the dermal thickness (DT), STT, SS, scar, and subcutaneous tissue EM on the right and left cheeks were measured by the same experienced radiologist with SWE. Appropriate statistical methods analyzed the results.

NCT ID: NCT05399290 Completed - Acne Vulgaris Clinical Trials

Subantimicrobial Doxycycline in Acne

Start date: November 19, 2020
Phase: Phase 4
Study type: Interventional

Antibiotic resistance is a public health problem that worsens the more physicians prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As such, clinicians can make a large impact by practicing good antibiotic stewardship while still addressing the impact of acne on adolescents' self-esteem. Subantimicrobial doxycycline maintains its anti-inflammatory effects while eliminating antimicrobial properties and associated risks of drug resistance. Few studies, focused primarily on adults, have shown that subantimicrobial doxycycline is efficacious in treating acne from a physician standpoint. The investigators aim to investigate the patient experience of acne treatment with subantimicrobial dose doxycycline in the pediatric population.